Cargando…

Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study

Active surveillance may be a safe and effective treatment in oesophageal cancer patients with a clinically complete response after neoadjuvant chemoradiotherapy (nCRT). In the NOSANO‐study we gained insight in patients' motive to opt for either an experimental treatment called active surveillan...

Descripción completa

Detalles Bibliográficos
Autores principales: Hermus, Merel, van der Wilk, Berend J., Chang, Rebecca T. H., Collee, Gerlise, Noordman, Bo J., Coene, Peter‐Paul L. O., Dekker, Jan Willem T., Hartgrink, Henk H., Heisterkamp, Joos, Nieuwenhuijzen, Grard A. P., Rosman, Camiel, Timmermans, Liesbeth, Wijnhoven, Bas P. L., van der Zijden, Charlène J., Busschbach, Jan J., van Lanschot, J. Jan B., Lagarde, Sjoerd M., Kranenburg, Leonieke W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092042/
https://www.ncbi.nlm.nih.gov/pubmed/36250325
http://dx.doi.org/10.1002/ijc.34327
_version_ 1785023254861185024
author Hermus, Merel
van der Wilk, Berend J.
Chang, Rebecca T. H.
Collee, Gerlise
Noordman, Bo J.
Coene, Peter‐Paul L. O.
Dekker, Jan Willem T.
Hartgrink, Henk H.
Heisterkamp, Joos
Nieuwenhuijzen, Grard A. P.
Rosman, Camiel
Timmermans, Liesbeth
Wijnhoven, Bas P. L.
van der Zijden, Charlène J.
Busschbach, Jan J.
van Lanschot, J. Jan B.
Lagarde, Sjoerd M.
Kranenburg, Leonieke W.
author_facet Hermus, Merel
van der Wilk, Berend J.
Chang, Rebecca T. H.
Collee, Gerlise
Noordman, Bo J.
Coene, Peter‐Paul L. O.
Dekker, Jan Willem T.
Hartgrink, Henk H.
Heisterkamp, Joos
Nieuwenhuijzen, Grard A. P.
Rosman, Camiel
Timmermans, Liesbeth
Wijnhoven, Bas P. L.
van der Zijden, Charlène J.
Busschbach, Jan J.
van Lanschot, J. Jan B.
Lagarde, Sjoerd M.
Kranenburg, Leonieke W.
author_sort Hermus, Merel
collection PubMed
description Active surveillance may be a safe and effective treatment in oesophageal cancer patients with a clinically complete response after neoadjuvant chemoradiotherapy (nCRT). In the NOSANO‐study we gained insight in patients' motive to opt for either an experimental treatment called active surveillance or for standard immediate surgery. Both qualitative and quantitative analyses methods were used. Forty patients were interviewed about their treatment preference, 3 months after completion of nCRT (T1). Data were recorded, transcribed verbatim and analysed according to the principles of grounded theory. In addition, at T1 and T2 (12 months after completion of nCRT) questionnaires on health‐related quality of life, coping, anxiety and decisional regret (only T2) were administered. Interview data analyses resulted in a conceptual model with ‘dealing with threat of cancer’ as the central theme. Patients preferring active surveillance tend to cope with this threat by confiding in their bodies and good outcomes. Their mind‐set is one of ‘enjoy life now’. Patients preferring surgery tend to cope by minimizing uncertainty and eliminating the source of cancer. Their mind‐set is one of ‘don't give up, act now’. Furthermore, questionnaire results showed that patients with a preference for standard surgery had a lower quality of life. Patient preferences are individualized and thus difficult to predict. Our model can help healthcare professionals to determine patient preferences for treatment. Coping style and mind‐set seem to be determining factors here.
format Online
Article
Text
id pubmed-10092042
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-100920422023-04-13 Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study Hermus, Merel van der Wilk, Berend J. Chang, Rebecca T. H. Collee, Gerlise Noordman, Bo J. Coene, Peter‐Paul L. O. Dekker, Jan Willem T. Hartgrink, Henk H. Heisterkamp, Joos Nieuwenhuijzen, Grard A. P. Rosman, Camiel Timmermans, Liesbeth Wijnhoven, Bas P. L. van der Zijden, Charlène J. Busschbach, Jan J. van Lanschot, J. Jan B. Lagarde, Sjoerd M. Kranenburg, Leonieke W. Int J Cancer Cancer Therapy and Prevention Active surveillance may be a safe and effective treatment in oesophageal cancer patients with a clinically complete response after neoadjuvant chemoradiotherapy (nCRT). In the NOSANO‐study we gained insight in patients' motive to opt for either an experimental treatment called active surveillance or for standard immediate surgery. Both qualitative and quantitative analyses methods were used. Forty patients were interviewed about their treatment preference, 3 months after completion of nCRT (T1). Data were recorded, transcribed verbatim and analysed according to the principles of grounded theory. In addition, at T1 and T2 (12 months after completion of nCRT) questionnaires on health‐related quality of life, coping, anxiety and decisional regret (only T2) were administered. Interview data analyses resulted in a conceptual model with ‘dealing with threat of cancer’ as the central theme. Patients preferring active surveillance tend to cope with this threat by confiding in their bodies and good outcomes. Their mind‐set is one of ‘enjoy life now’. Patients preferring surgery tend to cope by minimizing uncertainty and eliminating the source of cancer. Their mind‐set is one of ‘don't give up, act now’. Furthermore, questionnaire results showed that patients with a preference for standard surgery had a lower quality of life. Patient preferences are individualized and thus difficult to predict. Our model can help healthcare professionals to determine patient preferences for treatment. Coping style and mind‐set seem to be determining factors here. John Wiley & Sons, Inc. 2022-10-27 2023-03-15 /pmc/articles/PMC10092042/ /pubmed/36250325 http://dx.doi.org/10.1002/ijc.34327 Text en © 2022 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Cancer Therapy and Prevention
Hermus, Merel
van der Wilk, Berend J.
Chang, Rebecca T. H.
Collee, Gerlise
Noordman, Bo J.
Coene, Peter‐Paul L. O.
Dekker, Jan Willem T.
Hartgrink, Henk H.
Heisterkamp, Joos
Nieuwenhuijzen, Grard A. P.
Rosman, Camiel
Timmermans, Liesbeth
Wijnhoven, Bas P. L.
van der Zijden, Charlène J.
Busschbach, Jan J.
van Lanschot, J. Jan B.
Lagarde, Sjoerd M.
Kranenburg, Leonieke W.
Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
title Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
title_full Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
title_fullStr Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
title_full_unstemmed Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
title_short Patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: The NOSANO‐study
title_sort patient preferences for active surveillance vs standard surgery after neoadjuvant chemoradiotherapy in oesophageal cancer treatment: the nosano‐study
topic Cancer Therapy and Prevention
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092042/
https://www.ncbi.nlm.nih.gov/pubmed/36250325
http://dx.doi.org/10.1002/ijc.34327
work_keys_str_mv AT hermusmerel patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT vanderwilkberendj patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT changrebeccath patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT colleegerlise patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT noordmanboj patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT coenepeterpaullo patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT dekkerjanwillemt patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT hartgrinkhenkh patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT heisterkampjoos patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT nieuwenhuijzengrardap patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT rosmancamiel patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT timmermansliesbeth patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT wijnhovenbaspl patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT vanderzijdencharlenej patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT busschbachjanj patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT vanlanschotjjanb patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT lagardesjoerdm patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy
AT kranenburgleoniekew patientpreferencesforactivesurveillancevsstandardsurgeryafterneoadjuvantchemoradiotherapyinoesophagealcancertreatmentthenosanostudy